Physician profile
Amin Radparvar
NPI 1316987837
$2,824.77
in general payments reported to CMS, 2019-2025
22 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $178 · 2021: $743 · 2022: $517 · 2023: $651 · 2024: $173 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000 · Gift: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.33 |
| Gift | $118.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $376.25 | 2023-2025 | Afrezza |
| Lilly USA, LLC | $337.60 | 2019-2025 | Mounjaro |
| Novo Nordisk INC | $314.70 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $260.23 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $246.17 | 2021-2024 | Farxiga |
| Medtronic Minimed, INC. | $187.32 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.83 | 2021-2023 | Jardiance |
| Amarin Pharma, INC. | $133.85 | 2020-2022 | |
| Medtronic, INC. | $114.40 | 2021-2022 | |
| Beta Bionics, INC. | $98.98 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $82.83 | 2022-2023 | |
| Abbvie INC. | $72.37 | 2021-2023 | |
| Dexcom, INC. | $70.36 | 2019-2021 | |
| Insulet Corporation | $61.38 | 2019-2021 | |
| Intuity Medical INC | $61.09 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $57.24 | 2023 | Prolia, Evenity |
| Sequel Med Tech, LLC | $55.86 | 2025 | Twiist |
| Pfizer INC. | $48.27 | 2025 | |
| Sanofi-Aventis U.S. LLC | $27.17 | 2022 | |
| Tandem Diabetes Care, INC. | $17.84 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.70 | 2025 | Unithroid |
| Lifescan, INC. | $14.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amin Radparvar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.